The FDA has recently approved Bayer’s oral androgen receptor inhibitor Nubeqa (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC), a serious form of prostate cancer.

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation therapy (ADT), reduced the risk of radiographic progression or death by 46% compared to ADT with placebo.

According to the drug’s website, men taking Nubeqa typically pay an average of $454 per month with Medicare coverage—though most pay under $50—while those with commercial insurance pay an average of $210 per month, with eligible patients potentially paying as little as $0 through the NUBEQA $0 Co-Pay Program.

The drug’s cost is a criti

See Full Page